Trial results for a study investigating the effects of meditation on plasma biomarkers of Alzheimer's Disease were posted on ClinicalTrials.gov on 2026-01-05. The study found that belly-focus concentration meditation led to a mean change of -0.38 Z-score in plasma amyloid beta levels, with an ANOVA p-value of 0.003 for overall amyloid beta changes.

Background

Alzheimer's Disease is a progressive neurodegenerative disorder characterized by cognitive decline, with amyloid beta (Aβ) plaques being a hallmark pathological feature. While the study participants were healthy adults aged 18-35, research into early life factors and potential preventative strategies, including lifestyle interventions, is crucial for understanding and mitigating future risk. Plasma biomarkers of Alzheimer's Disease, such as amyloid beta levels, are increasingly being investigated as potential indicators of risk or early pathological changes, even in individuals without clinical symptoms. Exploring non-pharmacological interventions like meditation that may influence these biomarkers could offer insights into brain health and disease prevention.

Trial design

This completed study, identified as Phase NA, enrolled 94 healthy adult participants aged 18-35. The trial aimed to examine how two types of concentration meditation practices affect plasma biomarkers of Alzheimer's Disease, as well as emotional well-being and episodic memory. Participants were asked to engage in one week of daily meditation practice or a no-intervention control task at home. Blood samples were collected before and after the intervention to assess plasma biomarkers. The interventions included:

Key outcomes measured included changes in plasma amyloid beta (Aβ) levels and the plasma Aβ42/40 ratio.

Key results

The trial results indicated varying effects on plasma amyloid beta levels across the intervention groups. For the first set of measurements of Change in Plasma Amyloid Beta (Aβ) Levels:

A second set of measurements for Change in Plasma Amyloid Beta (Aβ) Levels showed:

Regarding the Change in Plasma Ab42/40 Ratio, all groups showed a consistent mean change of 0.05 (Standard Error ranging from 0.001 to 0.002) in the ratio of Aβ42 to Aβ40.

Statistical analyses using ANOVA revealed a significant finding for one outcome, with an F test value of 6.21 and a corresponding p-value of 0.003. Other ANOVA results included an F test value of 0.78 with a p-value of 0.46, an F test value of 2.13 with a p-value of 0.127, and an F test value of 0.004 with a p-value of 0.952.

What this means

The results suggest that short-term belly-focus concentration meditation practices may influence plasma amyloid beta levels in healthy young adults. Specifically, the observed decrease in plasma Aβ levels in the meditation groups, contrasting with an increase in the control group, warrants further investigation. The significant ANOVA p-value of 0.003 supports a notable difference in Aβ changes across the groups. However, the plasma Aβ42/40 ratio did not show substantial changes across any of the intervention or control arms. These findings, while preliminary and conducted in a young, healthy population, open avenues for exploring meditation as a potential lifestyle factor influencing biomarkers associated with Alzheimer's Disease risk. Further research is needed to understand the long-term effects and clinical relevance of these biomarker changes in relation to neurodegenerative disease prevention.

Source

The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06210035, titled "Effects of Heart Rate Oscillations During Meditation on Plasma Biomarkers of Alzheimer's Disease", were posted on 2026-01-05 on clinicaltrials.gov.